TGFB1 and myelodysplastic syndrome: Consistent with this, our results showed that T-lymphocyte proliferation suppressed by MDS-MSC could be restored by high dose of anti-rhTGF-β1 (≥0.5 μg/mL), indicating the inhibitory effects of MDS-MSC were mediated by soluble factor of TGF-β1.